Epidemiology and Psychiatric Sciences
2026
Wen Tang, Wei-Wei Jiang, Wen-Qian Que et al.
Abstract Aims To synthesize the available experimental study evidence to estimate the effects of ketamine on suicide ideation (SI) in high-risk individuals. Methods We conducted a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Double-blind randomized controlled trials and open-label studies investigating...
Epidemiology and Psychiatric Sciences
January 16, 2023
Rosa Ritunnano, D Papola, Matthew R Broome et al.
32 citations
This editorial reflects on current methodological trends in translational research in mental health. It aims to build a bridge between two fields that are frequently siloed off from each other: interventional research and phenomenologically informed research. Recent years have witnessed a revival of phenomenological approaches in mental health, often - but not only - as a means of connecting...
Epidemiology and Psychiatric Sciences
2023
Gianfranco Di Gennaro, Marco Colizzi
Abstract The psychoactive properties of cannabis have been known forever. Since 1987, several prospective studies have suggested an increased risk of psychosis among cannabis users, with alternative explanations failing to account for such an effect. A cause–effect relationship has thus been implied. Further evidence has indicated that there is a dose–response relationship, and high-potency...
Epidemiology and Psychiatric Sciences
2020
Chiara Gastaldon, D. Papola, G. Ostuzzi et al.
Abstract In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ketamine has not been approved for depression in the USA or in any other country, it...
Epidemiology and Psychiatric Sciences
2020
Chiara Gastaldon, D. Papola, G. Ostuzzi et al.
Abstract Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval.
Epidemiology and Psychiatric Sciences
March 29, 2011
Alberto Chiesa, Paolo Brambilla, Alessandro Serretti
20 citations
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.